

# Michael R Freeman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1505520/publications.pdf>

Version: 2024-02-01

73  
papers

3,080  
citations

218677  
26  
h-index

168389  
53  
g-index

77  
all docs

77  
docs citations

77  
times ranked

5725  
citing authors

#	ARTICLE	IF	CITATIONS
1	Extracellular Vesicles in Cancer: Exosomes, Microvesicles and the Emerging Role of Large Oncosomes. <i>Seminars in Cell and Developmental Biology</i> , 2015, 40, 41-51.	5.0	675
2	Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. <i>Oncotarget</i> , 2015, 6, 11327-11341.	1.8	289
3	Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1505403.	12.2	286
4	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. <i>Cancer Research</i> , 2016, 76, 4948-4958.	0.9	147
5	MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 2306-2317.	0.9	119
6	ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. <i>Nature Medicine</i> , 2018, 24, 1887-1898.	30.7	113
7	The current evidence on statin use and prostate cancer prevention: are we there yet?. <i>Nature Reviews Urology</i> , 2017, 14, 107-119.	3.8	111
8	Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. <i>Journal of Pathology</i> , 2013, 231, 77-87.	4.5	93
9	CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 1662-1673.	0.9	83
10	RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. <i>Endocrine-Related Cancer</i> , 2014, 21, 311-326.	3.1	74
11	Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 252-259.	3.9	71
12	Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 409-418.	3.4	64
13	Large and small extracellular vesicles released by glioma cells <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1689784.	12.2	57
14	Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. <i>Cancer Research</i> , 2018, 78, 6086-6097.	0.9	49
15	Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes. <i>Scientific Reports</i> , 2015, 5, 12136.	3.3	48
16	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 320-329.	7.0	46
17	High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients. <i>RNA Biology</i> , 2017, 14, 305-316.	3.1	43
18	Genes involved in prostate cancer progression determine MRI visibility. <i>Theranostics</i> , 2018, 8, 1752-1765.	10.0	43

#	ARTICLE	IF	CITATIONS
19	A Transcriptional Regulatory Loop of Master Regulator Transcription Factors, PPARC, and Fatty Acid Synthesis Promotes Esophageal Adenocarcinoma. <i>Cancer Research</i> , 2021, 81, 1216-1229.	0.9	41
20	Comprehensive palmitoylâ€proteomic analysis identifies distinct protein signatures for large and small cancerâ€derived extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1764192.	12.2	37
21	27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6â€JAKâ€STAT3 Signaling in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2020, 18, 671-684.	3.4	35
22	Cultured circulating tumor cells and their derived xenografts for personalized oncology. <i>Asian Journal of Urology</i> , 2016, 3, 240-253.	1.2	33
23	Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 84645-84657.	1.8	33
24	Low-Background Acyl-Biotinyl Exchange Largely Eliminates the Coisolation of Non- <i>S</i> -Acylated Proteins and Enables Deep <i>S</i> -Acylproteomic Analysis. <i>Analytical Chemistry</i> , 2019, 91, 9858-9866.	6.5	32
25	SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. <i>Oncotarget</i> , 2015, 6, 44072-44083.	1.8	29
26	Keratin 8 is a potential self-antigen in the coronary artery disease immunopeptidome: A translational approach. <i>PLoS ONE</i> , 2019, 14, e0213025.	2.5	28
27	Personalization of prostate cancer therapy through phosphoproteomics. <i>Nature Reviews Urology</i> , 2018, 15, 483-497.	3.8	25
28	Optimization of DNA extraction from human urinary samples for mycobionome community profiling. <i>PLoS ONE</i> , 2019, 14, e0210306.	2.5	25
29	Can Stroma Reaction Predict Cancer Lethality?. <i>Clinical Cancer Research</i> , 2013, 19, 4905-4907.	7.0	24
30	Integration of proteomic and transcriptomic profiles identifies a novel PDGF-MYC network in human smooth muscle cells. <i>Cell Communication and Signaling</i> , 2014, 12, 44.	6.5	24
31	Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 419-428.	3.9	22
32	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. <i>Cancers</i> , 2018, 10, 379.	3.7	21
33	Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. <i>Prostate</i> , 2017, 77, 446-457.	2.3	20
34	Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 196-203.	3.9	20
35	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. <i>Theranostics</i> , 2019, 9, 2812-2826.	10.0	20
36	Ethanol Induced Disordering of Pancreatic Acinar Cell Endoplasmic Reticulum: An ER Stress/Defective Unfolded Protein Response Model. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 479-497.	4.5	19

#	ARTICLE	IF	CITATIONS
37	Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. <i>Nature Communications</i> , 2022, 13, 669.	12.8	19
38	Technologies and Challenges in Proteomic Analysis of Protein S-acylation. <i>Journal of Proteomics and Bioinformatics</i> , 2014, 07, 256-263.	0.4	18
39	Regulation of inside-out $\beta$ 1-integrin activation by CDCP1. <i>Oncogene</i> , 2018, 37, 2817-2836.	5.9	17
40	Quantitative proteomic analysis of prostate tissue specimens identifies deregulated protein complexes in primary prostate cancer. <i>Clinical Proteomics</i> , 2019, 16, 15.	2.1	15
41	A comparative study of PCS and PAM50 prostate cancer classification schemes. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 733-742.	3.9	14
42	Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity. <i>Clinical Cancer Research</i> , 2022, 28, 414-424.	7.0	14
43	Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. <i>BMC Cancer</i> , 2020, 20, 398.	2.6	13
44	Antioxidant functions of DHHC3 suppress anti-cancer drug activities. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 2341-2353.	5.4	12
45	Trading in your spindles for blebs: the amoeboid tumor cell phenotype in prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 530.	1.6	12
46	Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4819-4832.	2.0	11
47	Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 425-428.	1.9	7
48	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. <i>European Urology Open Science</i> , 2022, 40, 19-26.	0.4	7
49	Universal Solid-Phase Reversible Sample-Prep for Concurrent Proteome and N-Glycome Characterization. <i>Journal of Proteome Research</i> , 2016, 15, 891-899.	3.7	5
50	Sex as a Determinant of Responses to a Coronary Artery Disease Self-Antigen Identified by Immune-Peptidomics. <i>Frontiers in Immunology</i> , 2020, 11, 694.	4.8	3
51	A Systems Approach to Prostate Cancer Classificationâ€™Response. <i>Cancer Research</i> , 2017, 77, 7133-7135.	0.9	2
52	Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?. <i>European Urology</i> , 2018, 74, 702-703.	1.9	2
53	miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. <i>Cancers</i> , 2021, 13, 5850.	3.7	2
54	BoxCar and shotgun proteomic analyses reveal molecular networks regulated by UBR5 in prostate cancer. <i>Proteomics</i> , 2022, 22, e2100172.	2.2	2

#	ARTICLE	IF	CITATIONS
55	Statin Drugs and Prostate Cancer: Time to Consider Proactive Strategies in Patients. <i>Journal of Urology</i> , 2013, 189, 1192-1193.	0.4	1
56	WALNUTS for POWER: A Protocol for the Polyphenols, Omega-3 Fatty Acids, Weight Loss, and Energy Randomized Controlled Trial. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa044_015.	0.3	1
57	Nuclear size of circulating tumor cells in advanced prostate cancer to reveal a potential biomarker for clinical outcomes and androgen receptor indifference.. <i>Journal of Clinical Oncology</i> , 2021, 39, 167-167.	1.6	1
58	A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vs CTC) association studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 208-208.	1.6	1
59	Development of a circulating tumor cell-based RNA classifier for patients with castration-resistant prostate cancer: CTC-PCS/PAM50.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17509-e17509.	1.6	1
60	Prostate cancer CTC-RNA Assay: A new method for contemporary genomics and precision medicine via liquid biopsy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 170-170.	1.6	1
61	A morphological subset of circulating tumor cells in advanced prostate cancer reveals a potential biomarker for clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17008-e17008.	1.6	0
62	A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16080-e16080.	1.6	0
63	A phase 2 study of cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vs CTC) association studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16552-e16552.	1.6	0
64	NanoVelcro CTC purification systems for expressional analysis of circulating tumor cells from prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 295-295.	1.6	0
65	Dynamic variations in gene expressions of circulating tumor cells in metastatic castration-resistant prostate cancer patients in response to androgen receptor signaling inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17063-e17063.	1.6	0
66	A noninvasive prognostic biomarker for metastatic castration-resistant prostate cancer: Very small nuclear circulating tumor cells.. <i>Journal of Clinical Oncology</i> , 2019, 37, 179-179.	1.6	0
67	A circulating tumor cell RNA assay for dynamic assessment of androgen receptor signaling inhibitors sensitivity in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 157-157.	1.6	0
68	Ultradeep Palmitoylâ€proteomic Analysis Uncovers Over 1,300 Novel Human Palmitoylâ€proteins. <i>FASEB Journal</i> , 2019, 33, 632.15.	0.5	0
69	A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5059-5059.	1.6	0
70	ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancer. <i>Translational Cancer Research</i> , 2019, 8, 2677-2679.	1.0	0
71	Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17512-e17512.	1.6	0
72	Association of very small nuclear circulating tumor cell (vs CTC) with clinical outcomes in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 168-168.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. American Journal of Clinical and Experimental Urology, 2021, 9, 350-366.	0.4	0